Reduce HRSA compliance issues that occur
during retrospective 340B claim classification.

Identify and Code 340B claims in real-time.


Flexible system capabilities for quick adaptability.


SCL 340B CARE maintains industry-leading technology.


SCL 340B CARE is the acknowledged leader in
340B program administration.


340B Administration Challenges

Complete 340B Solution

In response to 340B administrative challenges, we developed SCL 340B CARE. With it, we are able to offer a complete solution that addresses every aspect of program administration and reduces the burdens associated with 340B.  The unique design of our solution allows clients to implement either a turn-key solution or a la carte services to compliment their existing program.

Real-Time Identification and Coding

Our capabilities extend to the real-time identification and coding of 340B claim. This reduces the HRSA compliance issues that occur during retrospective claim classification.

Real-time Processing

SCL 340B CARE offers the industry’s first real-time 340B adjudication platform. We administer 340B management and network development nationwide for Not-for-Profit, DSH, Federally Qualified Health Centers (FQHC) and other 340B qualified entities. Our technology and administration provides eligible entities the ability to provide more patients access to lower drug costs while reducing administrative costs.

340B CARE Blog

  • In 2015, the 340B Drug Discount Program saved healthcare providers $6 billion on drug acquisition costs. While the program aims to make pharmaceutical and clinical care affordable and accessible to low-income patients; there is evidence that some participating entities are exploiting its discounts for profit. Since......

  • The 340B drug discount program helps disproportionate share hospitals (DSHs) to serve low-income patients. The stated objective of the 340B drug discount program is to “stretch federal resources as far as possible reaching more eligible patients and providing more comprehensive services.” Over time the program......

  • A recent opinion article by Tara O’Neill Hayes outlines arguments for CMS’ “Final 340B Rule.” The Centers for Medicare and Medicaid Services greeted the new year by slashing what Medicare pays hospitals for specific drugs by up to 30 percent. Consequently, Hospitals are vehemently against this decision.......